Literature DB >> 527350

Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease.

B Angelkort, N Maurin, K Boateng.   

Abstract

Impaired red cell deformability has been found in patients suffering from chronic peripheral vascular disorders, the implication being that microcirculatory blood flow is hindered and tissue hypoxaemia is aggravated. Measurement of erythrocyte deformability by a standard filtration technique for whole blood was carried out in 40 young healthy persons, in 25 untreated patients with peripheral occlusive arterial disease and in 25 patients with matching vascular disease, before and after a 6-weeks' oral treatment with 400 mg pentoxifylline 4-times daily. The filtration rates were significantly lower in the patient groups compared to those of healthy volunteers. After the oral administration of pentoxifylline, a significant increase in filtration rates was observed pointing to an improvement in erythrocyte deformability. The findings suggest that by improving erythrocyte deformability pentoxifylline positively influences the microcirculatory blood fluidity, an important factor for efficient therapy in peripheral arterial occlusive disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 527350     DOI: 10.1185/03007997909109432

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  10 in total

1.  Pentoxifylline in arterial disease of the legs.

Authors:  R Verhaeghe; M Verstraete
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.

Authors:  G Ciuffetti; M Mercuri; C Ott; R Lombardini; R Paltriccia; G Lupattelli; L Santambrogio; E Mannarino
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effect of pentoxifylline on single red cell deformability.

Authors:  D Seiffge; H Kiesewetter
Journal:  Klin Wochenschr       Date:  1981-11-16

4.  Effects of pentoxifylline (Trental) on blood flow, viscosity, and oxygen transport in young adults with inoperable cyanotic congenital heart disease.

Authors:  W Berman; N Berman; D Pathak; S C Wood
Journal:  Pediatr Cardiol       Date:  1994 Mar-Apr       Impact factor: 1.655

Review 5.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  Erythrocyte deformability in peripheral occlusive arterial disease.

Authors:  D Bareford; G S Lucas; N M Caldwell; P C Stone; S Baar; J Stuart
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

7.  The effect of denbufylline on the viscosity of rat whole blood and on the deformability (filterability) of rat blood cell suspensions.

Authors:  J J Jukna; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

Review 8.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

9.  Treatment of homozygous sickle cell disease with pentoxifylline.

Authors:  A Sacerdote
Journal:  J Natl Med Assoc       Date:  1999-08       Impact factor: 1.798

10.  Effects of pentoxifylline on oxygenation and exercise tolerance in patients with severe chronic obstructive pulmonary disease.

Authors:  Mohammad Javad Fallahi; Seiyed Mohammad Ali Ghayumi; Ali Reza Moarref
Journal:  Iran J Med Sci       Date:  2013-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.